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Australian general practitioners treat a median of 
5–7 palliative patients each year1 – a small part of 
their total clinical practice. However, it is care that 
patients and their families value greatly and, if 
done well, stands out in people’s minds as a very 
special encounter. Patients with end stage disease 
may have unpredictable crises requiring emergency 
assessment and treatment after hours. Frequently 
encountered acute problems may include nausea, 
vomiting, dyspnoea, delirium and pain, which occur 
in many life limiting illnesses including cancer, HIV/
AIDS, end stage organ failure and neurodegenerative 
diseases such as multiple sclerosis or motor 
neurone disease.
	
Decision	 making	 as	 the	 end	 of	 life	 approaches	 can	
be	 challenging.	 Patients	 may	 no	 longer	 want	 active	
investigation	 and	management,	 or	may	 be	 unrealistic	
about	 what	 is	 still	 achievable,	 especially	 at	 home.	
Assessment	 of	 the	 patient’s	 disease	 trajectory	 and	
potentially	 reversible	pathologies	may	be	difficult	 in	 the	
after	hours	setting.	Nonetheless,	 the	clinical	 imperative	
is	 to	 relieve	acute,	distressing	symptoms,	and	offer	 the	
possibility	 of	 appropriate	management	 at	 home	 if	 the	
patient	and	caregiver	wish,	and	when	appropriate.	
	 The	 doctor’s	 bag	 contains	 injectable	 emergency	
medications,	 some	 of	which	 have	 off-license	 but	well	
accepted	 indications	for	palliative	care,	 that	can	provide	
excellent	symptom	control	 (Table 1, 2).	Appropriate	use	
of	 these	medications	 for	 palliation	 in	 a	 crisis	 requires	
consideration	 of	 route	 of	 administration,	 appropriate	
doses,	 knowledge	 of	 the	 duration	 of	 effect,	 and	 of	
adverse	 effects	 relevant	 in	 the	 emergency	 setting.	The	
preferred	parenteral	route	of	administration	for	palliative	
medications	 is	 subcutaneous.	 It	 is	worthwhile	 to	 carry	
subcutaneous	 butterfly	 needles	 in	 the	 emergency	 bag	
as	 inserting	 a	 butterfly	 for	 repeated	 doses	 is	 less	
traumatic	for	the	patient.	Suggested	dosages	are	taken,	
wherever	 possible,	 from	 the	Therapeutic guidelines	 for	
palliative	care.2
Nausea and vomiting
Nausea	 and	 vomit ing	 are	 common,	 unpleasant	
symptoms	 in	 patients	 with	 cancer	 and	 other	 end	
stage	 diseases.	 Assessment	 aims	 to	 identify	 an	
underlying	 cause.	 Causes	may	 relate	 to	 the	 disease	
process	 (eg.	 cerebral	 metastases),	 to	 treatment	 (eg.	
chemotherapy),	 or	 be	 unrelated	 (eg.	 gastroenteritis).3	
It	 is	 often	 multifactorial.	 Assessment	 should	 focus	
on	 distinguishing	 potentially	 reversible	 presentations	
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requiring	more	 urgent	 attention	 (eg.	 bowel	
obstruction,	 raised	 intracranial	 pressure)	 from	
those	 that	 can	 be	managed	 symptomatically	
pending	 further	 review.	 I t 	 a lso	 guides	
medication	 choice.	 For	 example,	 prokinetic	
effects	 of	 metoclopromide	 are	 helpful	 in	
gastric	stasis	but	are	likely	to	worsen	vomiting	
and	 colicky	 pain	 in	 complete	 gastrointestinal	
obstruction.4	 Unheralded	 vomiting	 suggests	
the	possibility	of	cerebral	metastases	or	very	
high	 bowel	 obstruction,	 and	 steroids	may	 be	
appropriately	used5,6	(Table 3).		
	 The	 doctor’s	 bag	 carries	 several	 drugs	
with	 antiemetic	 activity:	 metoclopramide,	
prochlorperazine,	 chlorpromazine,	 haloperidol,	
dexamethasone , 	 hyd roco r t i sone , 	 and	
promethazine.	 Parenteral	 forms	 can	 be	
administered	 subcutaneously	 rather	 than	
intramuscularly	 except	 prochlorperazine	 and	
chlorpromazine,	 which	 may	 only	 be	 given	
intravenously	or	intramuscularly.
Dyspnoea
Dyspnoea	may	be	insidious,	often	worsens	as	
death	 approaches,	 and	 in	 some	 patients	 no	
reversible	causes	will	be	identifiable	(Table 4).	
Several	randomised	controlled	trials	using	oral	
or	 parenteral	 opioids	 for	 dyspnoea	 in	 people	
with	 a	 range	 of	 life	 limiting	 illnesses	 have	
shown	 beneficial	 effect.7,8	 Pain	 and	 dyspnoea	
are	 potent	 stimulants	 of	 respiratory	 drive;	 by	
modulating	 the	 respiratory	 drive,	 morphine	
lessens	 distress	 associated	 with	 severe	
dyspnoea,	 reducing	 respiratory	 effort	without	
changing	 respiratory	 rate.9	 Benzodiazepines	
are	 sometimes	 recommended	 to	 t reat	
Table 1. Doctor’s bag medications and their indications for palliation
Medication and form Palliative care indication Mode of action Comment
Adrenaline  Malignant bleeding Vasoconstriction Can be used topically (ie. adrenaline soaked gauze) for small volume 
Injection 1 mg/mL (1 in 1000)    bleeding at superficial sites otherwise difficult to control (eg. fungating wounds)
Atropine  Noisy breathing/terminal secretions (‘death rattle’) Anticholinergic – may reduce bronchial secretions Side effects of atropine can be distressing for conscious or semiconscious patients.  
Injection 600 µg in 1 mL   Terminal secretions do not always require treatment. Treatment is often ineffective 
    once secretions are well established. Repositioning may reduce breathing noises
Chlorpromazine  Nausea Antipsychotic with antiemetic action via dopamine Haloperidol preferred as it can be given subcutaneously and is less sedating than 
Injection 50 mg in 2 mL  Delirium/acute confusional state antagonism at the chemoreceptor trigger zone chlorpromazine, and (unlike metoclopromide) has no prokinetic effect 
OR 
Haloperidol 
Injection 5 mg in 1 mL 
Dexamethasone  Central causes of nausea and vomiting, raised intracranial Corticosteroids – act to reduce malignant Dexamethasone is the more commonly used drug for these indications, but 
Injection 4 mg in 1 mL  pressure, malignant spinal cord compression, neuropathic inflammation and cytokine production, reduce equipotent dose of hydrocortisone is a reasonable alternative. 
OR pain or other poorly controlled pain, superior vena cava perineural oedema, mechanism of antiemetic High dose dexamethasone (16 mg daily) may prevent long term neurological 
Hydrocortisone obstruction, dyspnoea caused by lymphangitis  effect not known consequences of some spinal cord compressions if started immediately. If 
Injection 100 mg in 2 mL   active treatment of cord compression or raised intracranial pressure is appropriate,  
or 250 mg in 2 mL   it should be instituted without delay and further investigations urgently arranged 
      
Diazepam  Agitation and restlessness, myoclonus, seizures, muscle spasm Benzodiazepine – GABA agonist, effective as Benzodiazepines can worsen delirium. If delirium is suspected an antipsychotic 
Injection 10 mg in 2 mL anxiety from dyspnoea or other difficult symptoms anticonvulsant, muscle relaxant and anxiolytic  should be used in preference to a benzodiazepine initially. Myoclonus suggests 
renal or hepatic encephalopathy or neuroexcitatory effects of medications including 
accumulating opioid metabolites. Further investigation may be appropriate 
depending on the stage of the patient’s disease. Benzodiazepines may precipitate or 
worsen hepatic encephalopathy due to cirrhotic liver disease 
Metoclopramide  Nausea Antiemetics which act by dopamine antagonism Metoclopramide is preferred as it can be given subcutaneously; contraindicated in
Injection 10 mg in 2 mL   at the chemoreceptor trigger zone; metoclopramide  suspected high bowel obstruction 
OR   is also prokinetic and increases tone in the  
Prochlorperazine   gastro-oesophageal sphincter  
Morphine  Pain Opioid agonist – mode of action in relieving dyspnoea   Morphine has been shown to relieve dyspnoea in end stage respiratory disease and
Injection 15 mg in 1 mL  Dyspnoea, acute pulmonary oedema not known, may act by modulating ventilatory should not be withheld from distressed patients because of underlying lung 
OR 30 mg in 1 mL  drive centrally   disease. Nebulised morphine has not been shown to be effective18 – the parenteral 
route is most appropriate in an emergency
Promethazine  Nausea (vestibular type in particular) Antihistamine – acts on vestibular apparatus and  Sedating effects of promethazine can also be beneficial in contributing to symptom 
Injection 50 mg in 2 mL Itch vomiting centre by H1 receptor antagonism control for selected patients. Considerable patient variability in response
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anxiety	 associated	with	 refractory	 dyspnoea	
in	 the	 terminally	 ill.10	Their	 use	 can	 only	 be	
extrapolated	 from	 their	 anxiolytic	 role	 and	
have	not	been	formally	studied	in	this	setting.
	 Patients	with	 lymphangitis	 carcinomatosis	
present	 with	 severe	 dyspnoea	 which	 may	
progress	 rapidly,	 often	 unrelieved	 by	 oxygen	
or	morphine.	 It	 is	most	 often	 seen	 in	 breast,	
lung	 and	 gastric	 cancers.	 Steroids	 may	 be	
tried	in	this	situation.6	
	 Noisy	respirations	at	the	end	of	life	(‘death	
rattle’)	 may	 upset	 the	 caregivers	 of	 a	 dying	
person.	 Antichol inergic	 medications	 are	
traditionally	 used,	 as	 an	 extension	 of	 their	
use	 in	 anaesthesia	 for	 managing	 airway	
secretions.	The	 side	 effect	 profile	 of	 atropine	
can	be	distressing	to	a	conscious	patient	 (dry	
mouth,	 tachycardia,	 urinary	 retention).	 It	may	
worsen	 confusion	 and	 delirium,	 because	 it	
crosses	 the	 blood-brain	 barrier.	 Repositioning	
the	patient	may	be	almost	as	beneficial.11
Delirium/acute confusional states
Delirium	 is	 common	 in	 patients	 approaching	
the	 end	 stage	 of	 life	 limiting	 illnesses,	 is	
underdiagnosed,	 and	 is	 associated	with	 poor	
prognosis.12	A	simple	tool	for	the	detection	of	
delirium	is	the	Confusion	Assessment	method	
(Table 5).	 Delirium	 is	 often	multifactorial	 and	
less	 than	 half	 of	 cases	 occurring	 at	 the	 end	
of	 life	 are	 reversible.13	 Delirium	 is	 distressing	
for	 patients,	 families	 and	 caregivers.	 It	may	
be	 hyperactive	 (two-thirds),	 hypoactive,	 or	
both,	 and	 is	 characterised	 by	 fluctuating	
poor	 concentration,	 confusion,	 and	 easy	
distractibility,	 making	 assessment	 of	 other	
Table 1. Doctor’s bag medications and their indications for palliation
Medication and form Palliative care indication Mode of action Comment
Adrenaline  Malignant bleeding Vasoconstriction Can be used topically (ie. adrenaline soaked gauze) for small volume 
Injection 1 mg/mL (1 in 1000)    bleeding at superficial sites otherwise difficult to control (eg. fungating wounds)
Atropine  Noisy breathing/terminal secretions (‘death rattle’) Anticholinergic – may reduce bronchial secretions Side effects of atropine can be distressing for conscious or semiconscious patients.  
Injection 600 µg in 1 mL   Terminal secretions do not always require treatment. Treatment is often ineffective 
    once secretions are well established. Repositioning may reduce breathing noises
Chlorpromazine  Nausea Antipsychotic with antiemetic action via dopamine Haloperidol preferred as it can be given subcutaneously and is less sedating than 
Injection 50 mg in 2 mL  Delirium/acute confusional state antagonism at the chemoreceptor trigger zone chlorpromazine, and (unlike metoclopromide) has no prokinetic effect 
OR 
Haloperidol 
Injection 5 mg in 1 mL 
Dexamethasone  Central causes of nausea and vomiting, raised intracranial Corticosteroids – act to reduce malignant Dexamethasone is the more commonly used drug for these indications, but 
Injection 4 mg in 1 mL  pressure, malignant spinal cord compression, neuropathic inflammation and cytokine production, reduce equipotent dose of hydrocortisone is a reasonable alternative. 
OR pain or other poorly controlled pain, superior vena cava perineural oedema, mechanism of antiemetic High dose dexamethasone (16 mg daily) may prevent long term neurological 
Hydrocortisone obstruction, dyspnoea caused by lymphangitis  effect not known consequences of some spinal cord compressions if started immediately. If 
Injection 100 mg in 2 mL   active treatment of cord compression or raised intracranial pressure is appropriate,  
or 250 mg in 2 mL   it should be instituted without delay and further investigations urgently arranged 
      
Diazepam  Agitation and restlessness, myoclonus, seizures, muscle spasm Benzodiazepine – GABA agonist, effective as Benzodiazepines can worsen delirium. If delirium is suspected an antipsychotic 
Injection 10 mg in 2 mL anxiety from dyspnoea or other difficult symptoms anticonvulsant, muscle relaxant and anxiolytic  should be used in preference to a benzodiazepine initially. Myoclonus suggests 
renal or hepatic encephalopathy or neuroexcitatory effects of medications including 
accumulating opioid metabolites. Further investigation may be appropriate 
depending on the stage of the patient’s disease. Benzodiazepines may precipitate or 
worsen hepatic encephalopathy due to cirrhotic liver disease 
Metoclopramide  Nausea Antiemetics which act by dopamine antagonism Metoclopramide is preferred as it can be given subcutaneously; contraindicated in
Injection 10 mg in 2 mL   at the chemoreceptor trigger zone; metoclopramide  suspected high bowel obstruction 
OR   is also prokinetic and increases tone in the  
Prochlorperazine   gastro-oesophageal sphincter  
Morphine  Pain Opioid agonist – mode of action in relieving dyspnoea   Morphine has been shown to relieve dyspnoea in end stage respiratory disease and
Injection 15 mg in 1 mL  Dyspnoea, acute pulmonary oedema not known, may act by modulating ventilatory should not be withheld from distressed patients because of underlying lung 
OR 30 mg in 1 mL  drive centrally   disease. Nebulised morphine has not been shown to be effective18 – the parenteral 
route is most appropriate in an emergency
Promethazine  Nausea (vestibular type in particular) Antihistamine – acts on vestibular apparatus and  Sedating effects of promethazine can also be beneficial in contributing to symptom 
Injection 50 mg in 2 mL Itch vomiting centre by H1 receptor antagonism control for selected patients. Considerable patient variability in response
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symptoms	 with	 a	 subjective	 component	
difficult	 (eg.	 pain	 or	 dyspnoea).	 Confusional	
states	 most	 likely	 to	 be	 reversible	 at	 the	
end	 of	 life	 are	 those	 related	 to	medications,	
sepsis,	 dehydration,	 and	 treatable	metabolic	
abnormalities	such	as	hypoxaemia.13
	 Haloperidol	 is	 the	 first	 line	 medication	
for	 treat ing	 del i r ium	 and	 can	 be	 given	
subcutaneously.14	 Benzodiazepines	 have	 no	
primary	 role	 in	 treating	 delirium	 and	 may	
worsen	it.15	However,	severe	agitated	delirium	
occurring	 in	 the	 last	 hours	 to	 days	 of	 life	
sometimes	 requires	 a	 sedating	 antipsychotic	
and	 the	 addition	 of	 a	 benzodiazepine,	which	
may	act	synergistically.	
Pain
Palliative	 care	 patients	with	 significant	 pain	
will	 require	 a	 strong	 opioid	 for	 adequate	
symptom	 relief.	The	 doctor’s	 bag	 contains	
injectable	morphine	 and	 tramadol.	Morphine	
is	 the	 preferred	 medication	 for	 palliation	
(Table 6).16	 Most	 doctors	 are	 familiar	 with	
morphine	use,	and	treatment	of	acute	pain	 in	
the	opioid	naïve	patient.	Difficulties	arise	with	
assessing	 opioid	 needs	 in	 patients	 already	
using	 regular	 opioids	 who	 have	 escalating	
pain,	 especially	 in	 calculating	 an	 appropriate	
crisis	 dose	 when	 the	 usual	 medication	 is	
different,	 or	 is	 taken	 by	 a	 different	 route	 (eg.	
transdermal	fentanyl	patch,	methadone,	or	oral	
Table 2. Suggested emergency management strategies for acute symptom control and palliation from the doctor’s bag
Nausea and vomiting
• Metoclopromide 10–20 mg subcutaneously, dose may be repeated if necessary, up to 120 mg over 24 hours OR
• Haloperidol* 0.5–2.5 mg subcutaneously, up to 5 mg over 24 hours OR
• Promethazine 10–25 mg subcutaneously, up to 100 mg over 24 hours
• Suspected central causes of vomiting: dexamethasone 8–16 mg subcutaneously as a single dose
Dyspnoea
• Opioid naïve patient: morphine 1–2 mg subcutaneously, repeat half hourly if needed 
•  Patients on regular opioids: morphine, statim dose should be calculated based on 30–50% increase on the fourth hourly dose of opioid1
• Persistent distress unrelieved by morphine: diazepam 2–5 mg intravenously, repeated half hourly if needed until agitation settles
Delirium
• Haloperidol 2.5–5.0 mg subcutaneously,2 titrate at half hourly intervals up to 15 mg in 24 hours OR
• Chlorpromazine 10–25 mg intravenously, titrate at half hourly intervals, up to 100 mg in 24 hours is a more sedating option
•  If the patient is agitated, distressed, and/or a risk to themselves or their caregivers, sedation may be required in addition to 
antipsychotic medication 
• Diazepam 2.5–10.0 mg intravenously,2 repeated in half an hour if needed, until sedation is achieved 
Pain
•  Opioid naïve: morphine 1.0–2.5 mg subcutaneously (frail, elderly) or 2.5–5.0 mg subcutaneously as an initial dose. In a crisis, the 
patient should be frequently reviewed and the dose titrated up or down by 30–50% according to effect
•  On opioids already, experiencing an acute exacerbation that is likely to be opioid sensitive: increase background and breakthrough 
doses of opioid by 30–50% and convert to parenteral morphine3
1.  On opioids already, with an acute change less likely to be opioid sensitive (eg. visceral or neuropathic pain): a single dose of dexamethasone 4–16 mg 
subcutaneously can be added to opioid
2.  Use lower end of dose range initially in those who are medication naïve, the frail and elderly to minimise side effects
3.  Breakthrough doses are one-sixth to one-twelfth of total daily dose. Conversion from oral to parenteral morphine is based on oral bioavailability of 
30–50%. Parenteral doses must therefore be calculated as half to one-third of the oral morphine dose
Table 3. Bowel obstruction – an emergency management strategy from the doctor’s bag
Assessment 
Often partial/subacute rather than complete. Symptoms vary depending on level and 
completeness of obstruction. Gastric splash suggests high level of obstruction. Bulky 
hepatomegaly can sometimes cause gastric outlet obstruction
Management 
Aim is to reduce gastric secretions, pain, nausea and vomiting, and inflammation 
at site of obstruction, using parenteral medications. A combination of medications 
usually needed for optimal comfort. Overhydration (>1 L/day) should be avoided as 
it increases volume of gastrointestinal secretions. Effective medical management is 
usually possible without use of nasogastric drainage in end stage disease
Medications
Haloperidol 0.5–5.0 mg subcutaneously is the most appropriate antiemetic as it will 
not worsen colicky pain (0.5–2.5 mg in the frail elderly)
Dexamethasone 8–16 mg subcutaneously reduces peritumour oedema and nausea, 
has been shown to speed resolution of malignant bowel obstruction
Parenteral opioid should be titrated for analgesia
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sustained	 release	 preparations	 of	 oxycodone,	
morphine	 or	 tramadol).	These	 patients	 are	
often	 undertreated	 in	 an	 acute	 pain	 crisis.	A	
30–50%	 increase	 in	 the	 total	 daily	 dose	 and	
also	 in	 the	 breakthrough	 dose	 of	 a	 patient	
on	 regular	 opioids	 is	 generally	 safe,	 and	 a	
conversion	 table	 can	 be	 consulted	 for	 the	
conversion	to	parenteral	morphine.2	
	 Corticosteroids	 can	 be	 helpful	 in	 patients	
with	 pain	 due	 to	 acute	 nerve	 compression,	
v iscera l 	 d istension, 	 ra ised	 intracrania l	
pressure	 and	 soft	 t issue	 inf i l trat ion.6,17	
Dexamethasone	can	be	given	subcutaneously.	
In	 a	 crisis	 an	 immediate	 dose	 is	 appropriate,	
however	ongoing	steroids	should	not	be	given	
after	 midday	 as	 they	 have	 the	 potential	 for	
significant	sleep	disturbance.
General considerations
Patients	with	end	stage	disease	may	progress	
into	 organ	 failure,	 and	 be	 frail	 and	 cachexic.	
Many	 are	 also	 elderly.	 Dose	 selection	 should	
take	these	factors	into	account,	often	starting	
at	the	lower	end	of	the	dose	range.	Arranging	
to	 review	 the	 effect	 of	 the	 initial	 dose	 and	
titrate	medications	is	the	safest	way	to	assure	
good	symptom	control.
Conclusion 
Some	 exacerbations	may	 be	 intermittent	 or	
self	 limiting,	 but	 new	 symptoms	 can	 also	
herald	progression	of	disease	and	sometimes	
the	 onset	 of	 the	 terminal	 phase.	 Patients	
and	 their	 families	 often	 have	 clear	 ideas	
about	where	 they	wish	 care	 to	 be	 provided	
at	 this	 time.	 For	 some	 people	 with	 a	 good	
level	 of	 function	 and	 an	 acute,	 unexpected	
deterioration,	 transfer	 to	 a	 hospital	 for	
invest igat ion	 and	 management	 may	 be	
appropriate.	 For	 others,	 it	 may	 result	 in	
needless	 hospitalisation	 for	 a	 problem	 that	
could	 have	 been	 effectively	managed	 in	 the	
community	 setting.	The	 option	 of	 care	 at	
home	 is	 often	 gratefully	 received,	 and	 good	
emergency	 symptom	 control	 contributes	 to	
this	being	a	possibility.	The	challenging	aspect	
of	 patient	 assessment	 as	 death	 approaches	
however	 is	 in	 judging	 the	 disease	 trajectory,	
and	helping	people	weigh	up	the	benefits	and	
burdens	 of	medical	 interventions	 that	might	
be	offered	for	potentially	reversible	symptoms,	
so	they	can	make	their	own	choices.	
	 Most	 pall iative	 care	 services	 provide	
advice	around	the	clock	and	can	assist	general	
practitioners.	Referral	 for	acutely	uncontrolled	
symptoms	 allows	 urgent	 follow	 up	 from	
the	 local	 palliative	 care	 team	 for	 ongoing	
Table 4. Possible causes of dyspnoea in terminally ill patients
Related to the disease 
• Lung tumour or metastases
• Lymphangitis carcinomatosis
• Pleural or pericardial effusion 
• Cardiac tamponade
• Superior vena cava obstruction
• Pulmonary embolism 
• Muscle weakness
• Anaemia 
• Psychological distress
Related to treatment of the disease
• Chemotherapy induced lung injury (eg. bleomycin, taxanes)
• Radiation pneumonitis (a late effect – months to years)
Comorbid or intercurrent problems
• Congestive cardiac failure 
• Exacerbation of chronic obstructive pulmonary disease 
• Pneumonia
• Multifactorial
Table 5. The Confusion Assessment method19
Feature Assessment
1.  Acute onset and  Usually obtained from a family member or nurse 
fluctuating course  and shown by positive responses to the following 
questions: ‘Is there evidence of an acute change in 
mental status from the patient’s baseline?’ ‘Did the 
abnormal behaviour fluctuate during the day, ie. tend to 
come and go, or increase and decrease in severity?’
2. Inattention  Shown by a positive response to the following: ‘Did the 
patient have difficulty in focusing attention, eg. being 
easily distracted or having difficulty keeping track of 
what was being said?’
3. Disorganised thinking  Shown by a positive response to the following: ‘Was 
the patient’s thinking disorganised or incoherent such as 
rambling or irrelevant conversation, unclear or illogical 
ideas, or unpredictable switching from subject to 
subject?’
4.  Altered level of  Shown by any other than ‘alert’ to the following: 
consciousness   ‘Overall, how would you rate this patient’s level of 
consciousness?’ 
 Normal = alert
 Hyperalert = vigilant
 Drowsy, easily aroused = lethargic
 Difficult to arouse = stupor
 Unarousable = coma
The diagnosis of delirium requires the presence of 1 and 2 plus either 3 or 4
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management,	and	additional	support	for	those	
caring	for	dying	people	at	home.
Conflict	of	interest:	none.
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Table 6. Choice of parenteral opioid from the doctor’s bag for palliation in a crisis
 Advantages Disadvantages
Morphine May be given subcutaneously  If there is a history of intolerance, give 
with an antiemetic. Avoid if possibility of 
hypersensitivity
 Is also effective for dyspnoea  Renally cleared – dose reduce in renal failure
 Clinical effect lasts 3–4 hours
  Upper dose only limited by side effects, and considered  
titration minimises these effects
 Can be used to initiate continuing analgesia with regular  
 oral or ongoing subcutaneous morphine (regularly or by  
 continuous infusion)
Tramadol Can be used if morphine sensitivity or intolerance Has an upper ceiling on dose, therefore not  
 Acts via serotonin and noradrenaline reuptake, therefore the ideal agent for palliation   
 may have a role in complex and neuropathic pain Dose reduce in renal failure, hepatic failure, 
 Duration of effect 6–9 hours and in the elderly
   Potential interaction with other analgesics, 
antidepressants and serotonergic agents 
– may precipitate seizures or serotonergic 
syndrome
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